Browse
Submit Data
Databases
API
Help

Dataset Information

22 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Accomplishments in 2008 in the management of gastrointestinal stromal tumors.

ABSTRACT: Overview of the Disease ProcessIncidencePrognosisPredictive MarkersCurrent General Therapy Standards in North America and EuropeLocalized or Potentially Resectable DiseaseUnresectable or Metastatic DiseaseAccomplishments During the YearTherapySurgical Issues and Perioperative TherapyImatinibSunitinibNew DrugsBiomarkersBasic and Other Translational ScienceWhat Needs to Be DoneFuture DirectionsComments on ResearchObstacles to Progress.

SUBMITTER: Renouf D

PROVIDER: S-EPMC2791388 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Accomplishments in 2008 in the management of gastrointestinal stromal tumors.

Renouf Daniel D Blay Jean-Yves JY Blanke Charles C

Gastrointestinal cancer research : GCR 20090901 5 Supplement 2

Overview of the Disease ProcessIncidencePrognosisPredictive MarkersCurrent General Therapy Standards in North America and EuropeLocalized or Potentially Resectable DiseaseUnresectable or Metastatic DiseaseAccomplishments During the YearTherapySurgical Issues and Perioperative TherapyImatinibSunitinibNew DrugsBiomarkersBasic and Other Translational ScienceWhat Needs to Be DoneFuture DirectionsComments on ResearchObstacles to Progress. ...[more]

PMID: 20011569

Similar Datasets

Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.

Project description:Overview of the Disease ProcessIncidencePrognostic FactorsGeneral Therapy StandardsAccomplishments and Lack of Accomplishments During the YearSomatostatin AnalogsPeptide Receptor-Targeted TherapySelective Internal Radiotherapy (SIRT)CYTOTOXIC THERAPIES: TemozolomideVEGF Pathway InhibitorsmTOR InhibitorsDevelopment of BiomarkersWhat Needs to be Done (Application of the Accomplishments)Controversies and DisagreementsHistologic Classification and Staging of Neuroendocrine TumorsClinical Trial Design and End PointsFuture Directions.

| S-EPMC2791386 | biostudies-literature

Accomplishments in 2008 in the management of esophageal cancer.

Project description:Overview of the Disease ProcessIncidencePrognostic or Predictive FactorsCurrent General Therapy StandardsSurgeryCombined Treatment ModalitiesAccomplishments in 2008TherapyBiomarkers & Basic ScienceWhat Needs to be DoneApplications of the AccomplishmentsControversies and DisagreementsSpecial PopulationsFuture DirectionsComments on ResearchObstacles to Progress.

| S-EPMC2791390 | biostudies-literature

Accomplishments in 2008 in the management of hepatobiliary cancers.

Project description:HEPATOCELLULAR CARCINOMA: EpidemiologyManagement of HCC-Standard Approaches and Reports During the Past Year SurgeryLocoregional Treatment Local AblationChemoembolizationOther Local Treatment ModalitiesSystemic TreatmentClinical Trial DesignBasic Science and Biomarkers Basic and Translational SciencePrognostic and Predictive Markers Prognostic MarkersPredictive MarkersAccomplishments and Future DirectionsApplication of the AccomplishmentsFuture Directions BILIARY TRACT CANCERS: Overview of the DiseaseManagement of Biliary Tract Cancers-Current Approaches and Reports During the Past Year Surgical Resection and Adjuvant TherapySystemic Therapy for Unresectable or Metastatic Biliary Tract Cancer Cytotoxic ChemotherapyCytotoxic Chemotherapy in Combination With Targeted AgentSingle-Agent Targeted TherapyCombination of Targeted AgentsBiologyFuture Directions.

| S-EPMC2791389 | biostudies-literature

Accomplishments in 2008 in the management of localized gastric cancer.

Project description:Overview of the Disease ProcessIncidencePrognostic or Predictive FactorsCurrent General Therapy StandardsSurgeryAdjuvant ChemoradiationPerioperative ChemotherapyAdjuvant Oral Fluoropyrimidine MonotherapyAccomplishments in 2008TherapyBiomarkers and Basic ScienceWhat Needs to Be DoneApplications of the AccomplishmentsControversies and DisagreementsSpecial PopulationsCurrent and Future DirectionsComments on ResearchObstacles to Progress.

| S-EPMC2791387 | biostudies-literature

Accomplishments in 2008 in the management of advanced gastroesophageal cancer.

Project description:Overview of the Disease Process IncidencePrognosisPrognostic or Predictive FactorsCurrent General Therapy Standards Regional VariationsEvidence for Individual AgentsAccomplishments in 2008 TherapyBiomarkersBasic ScienceWhat Needs to be Done Applications of the AccomplishmentsControversies and DisagreementsSpecial PopulationsFuture Directions Comments on ResearchObstacles to Progress.

| S-EPMC2791384 | biostudies-literature

Advances and Challenges on Management of Gastrointestinal Stromal Tumors.

Project description:Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for over 5,000 newly diagnosed cases in the United States. The discovery of activated KIT and PDGFRA mutations and introduction of imatinib revolutionized the treatment strategy and opened up the new era of target therapy for solid tumors. Although surgery remains the primary modality of treatment for curative purpose, almost half of the patients experienced disease recurrence. Tailoring (neo)-adjuvant treatment with imatinib is ongoing to meet the need for an effective therapy. Currently, two drugs (sunitinib and regorafenib) have obtained Food and Drug Administration approval for GISTs after imatinib failure. However, most of the patients eventually progress due to primary or secondary resistance. Deeper understanding of the molecular mechanisms will guide us to develop personalized strategies in the future. Discussion in this review includes current standard management and the most recent advances and multiple ongoing clinical trials with different approaches. This review will provide further steps to be taken to conquer refractory disease.

| S-EPMC5949718 | biostudies-literature

Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Project description:Overview of the Disease IncidencePrognosisCurrent Therapy Standards Colorectal Liver Metastases (CRLM) Resectable TumorsStrategies to Convert Nonresectable Liver Metastases to Resectable StatusSynchronous Colorectal Liver MetastasesPredictors of Survival After Resection of CRLMPeritoneal Carcinomatosis (PC) From Colorectal CancerColorectal Pulmonary Metastases (CRPM)Colorectal Liver Metastases With Extrahepatic DiseaseAccomplishments (or Lack of Accomplishments) During the Year Therapy New Staging SystemSystemic Chemotherapy in Resectable Liver MetastasesSystemic Chemotherapy in Nonresectable Liver MetastasesSelective Internal Radiation Therapy (SIRT)Selection of Patients for Liver ResectionRadiofrequency AblationBiomarkersWhat Needs To Be Done? Optimizing Patient CareFuture Directions Comments on ResearchObstacles to Overcome.

| S-EPMC2791382 | biostudies-literature

Latest Advances in the Management of Pediatric Gastrointestinal Stromal Tumors.

Project description:Gastrointestinal stromal tumor is the most common mesenchymal neoplasm of the gastrointestinal tract, usually found in elderly adults. It is infrequent among pediatric patients and usually differs biologically from adult-type diseases presenting mutations of KIT and PDGFR genes. In this population, more frequent is the wild-type GIST possessing SDH, TRK, RAS, NF1 mutations, among others. Both tumor types require individualized treatment with kinase inhibitors that are still being tested in the pediatric population due to the different neoplasm biology. We review the latest updates to the management of pediatric gastrointestinal tumors with a particular focus on the advances in molecular biology of the disease that enables the definition of possible resistance. Emerging treatment with kinase inhibitors that could serve as targeted therapy is discussed, especially with multikinase inhibitors of higher generation, the effectiveness of which has already been confirmed in the adult population.

| S-EPMC9599787 | biostudies-literature

Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.

Project description:Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Before the advent of tyrosine kinase inhibitors (TKIs) there were few treatment options available to patients with metastatic GIST. Surgery was the mainstay of treatment and the prognosis was dismal. With the advent of imatinib and second-line TKIs the prognosis of metastatic GIST has improved dramatically; however, there is still a need for therapies for patients with disease refractory to TKI therapy. Newer agents are under investigation and may have promise. This article discusses the current standard of care in terms of standard and investigational pharmacotherapy in the management of metastatic GIST.

| S-EPMC3792495 | biostudies-literature

Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.

Project description:The therapeutic implications of the genomic alterations seen within the drivers of gastrointestinal stromal tumors (GIST) are among the best understood in all of solid tumors. Sequencing of cKIT and PDGFR? should be considered standard practice for the treatment of GIST patients. In this article, we will review the common mutations and how they are utilized in clinical management. In addition, we will review the rare D842V PDGFR? mutation and the diverse molecular group that lacks a mutation in either cKIT or PDGFR? (wild-type GIST) which are best treated on clinical trial. Finally, we will look forward at the future therapies that are ever evolving for management of GIST. Taken together, the scientific advances in understanding the molecular basis of GIST validates the importance of knowing and understanding the mutations that are present in any one patient.

| S-EPMC5506287 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data